March 15, 2012

Eurofins announces the launch of its Webinar services geared towards the food and feed industry. The service will leverage Eurofins' worldwide strength in laboratory analysis, and draw on the expertise of the Group's scientists and external experts across a wide range of competencies in the food and feed industry.

The first in the planned series of Webinars will be held on 23 March 2012, and will focus on 'New Allergen Action Levels, VITAL 2.0 and the Required Changes in Risk Management'. The webinar will address issues regarding the use of analytical methodology for quality assurance and enforcement in the context of emerging action levels. The second Webinar is scheduled for the 25th of April, 2012 and will focus on 'Gluten-free Claims: reliability and liability'. The topic is gaining importance following the recent publication of an article by Bert Popping and Carmen Diaz Amigo in the special section of the Journal of AOAC International, discussing deficiencies of some of the current analytical approaches.

Eurofins' Webinar services seek to gather and condense information on the most important issues relevant to the industry from various channels, to ensure that regulatory affairs specialists, quality control and production managers stay well-informed, which is key to succeeding in the business environment. Information will be delivered in a concise and effective manner, and will offer relevant insight from leading specialists and industry players.

The Webinars are specifically tailored to benefit upper-management levels in the industry, by synthesizing the most significant issues that affect their businesses, maximizing efficiency by reducing the amount of time required to stay on top of all relevant information, and eliminating the need to travel.  The sessions will be conducted initially in English and German, with plans to be rolled-out in other languages in the future.

As the world leader in food analytical testing, Eurofins has developed the widest portfolio of testing methods, covering the broadest range of analytical concerns within the industry. The Group is also the world leader in pharmaceutical products testing and in environmental laboratory services, and is one of the global market leaders in agroscience, genomics and central laboratory services. Eurofins' employees actively engage in roundtables and other discussions with both industry and regulatory bodies to develop methodologies and frameworks, and as such, it is well-positioned to offer meaningful contribution to discussions on issues that are most relevant to the industry.

Eurofins Webinars can be found at www.eurofins-conferences.com/webinars

For further information please contact:

Eurofins Conferences

Dr. Bert Pöpping

Phone:    +494049294-600

E-mail:     bertpoppimg@eurofins.com

Investor Relations and Corporate Communications

Phone:    +32-2-769 7383   

E-mail:     ir@eurofins.com

Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With over 10,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and, if requested, expert advice by its highly qualified staff.

The Group is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services, and one of the global market leaders in agroscience, genomics and central laboratory services. It intends to pursue its dynamic growth strategy and expand both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the NYSE Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific' management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.